J. William Owens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. William Owens has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
John Ashby
Syngenta Central Toxicology Laboratory, Macclesfield, Cheshire, UK
4 shared publicationsErrol Zeiger
Errol Zeiger Consulting, Chapel Hill, North Carolina, USA
2 shared publications- Leon Earl Gray
U.S. Environmental Protection Agency, Office of Research & Development, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, USA
2 shared publications Lesley Onyon
World Health Organization, Geneva, Switzerland
2 shared publicationsMichael Walker
Health Canada, Ottawa, Ontario, Canada
2 shared publicationsElard Jacob
BASF, Ludwigshafen, Germany
1 shared publication
Latest Publications
- Open Access
- 1 May 2007
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 115 (5) , 671-678
The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses: Phase 2 Dose–Response Studies
ObjectiveThe Organisation for Economic Co-operation and Development (OECD) has completed phase 2 of an international program to validate the rodent Hershberger bioassay.DesignThe Hershberger bioassay is designed to identify suspected androgens and antiandrogens based on changes in the weights of five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, the levator ani and bulbocavernosus muscles, the glans penis, and paired Cowper’s or bulbourethral glands). Protocol sensitivity and reproducibility were tested using two androgen agonists (17α-methyl testosterone and 17β-trenbolone), four antagonists [procymi-done, vinclozolin, linuron, and 1,1-dichoro-2,2-bis-(p-chlorophenyl)ethylene (p,p’-DDE)], and a 5α-reductase inhibitor (finasteride). Sixteen laboratories from seven countries participated in phase 2.ResultsIn 40 of 41 studies, the laboratories successfully detected substance-related weight changes in one or more tissues. The one exception was with the weakest...
- 1 May 2007
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 115 (5) , 671-678
Open AccessThe OECD Program to Validate the Rat Hershberger Bioassay to Screen Compounds for in Vivo Androgen and Antiandrogen Responses: Phase 2 Dose–Response Studies
ObjectiveThe Organisation for Economic Co-operation and Development (OECD) has completed phase 2 of an international program to validate the rodent Hershberger bioassay.DesignThe Hershberger bioassay is designed to identify suspected androgens and antiandrogens based on changes in the weights of five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, the levator ani and bulbocavernosus muscles, the glans penis, and paired Cowper’s or bulbourethral glands). Protocol sensitivity and reproducibility were tested using two androgen agonists (17α-methyl testosterone and 17β-trenbolone), four antagonists [procymi-done, vinclozolin, linuron, and 1,1-dichoro-2,2-bis-(p-chlorophenyl)ethylene (p,p’-DDE)], and a 5α-reductase inhibitor (finasteride). Sixteen laboratories from seven countries participated in phase 2.ResultsIn 40 of 41 studies, the laboratories successfully detected substance-related weight changes in one or more tissues. The one exception was with the weakest...
- Open Access
- 1 August 2006
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 114 (8) , 1259-1265
The OECD Program to Validate the Rat Hershberger Bioassay to Screen Compoundsfor in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonistand a Potent Antagonist to Test the Standardized Protocol
The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity.
- 1 August 2006
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 114 (8) , 1259-1265
Open AccessThe OECD Program to Validate the Rat Hershberger Bioassay to Screen Compoundsfor in Vivo Androgen and Antiandrogen Responses. Phase 1: Use of a Potent Agonistand a Potent Antagonist to Test the Standardized Protocol
The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no androgenic activity.
- 30 November 2005
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 43 (2) , 194-202
Weighing the results of differing ‘low dose’ studies of the mouse prostate by Nagel, Cagen, and Ashby: Quantification of experimental power and statistical results
- 30 November 2005
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 43 (2) , 194-202
Weighing the results of differing ‘low dose’ studies of the mouse prostate by Nagel, Cagen, and Ashby: Quantification of experimental power and statistical results
- Open Access
- 1 October 2004
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 112 (14) , A795-A796
Conflicts of Interest: Owens’ Response
- 1 October 2004
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 112 (14) , A795-A796
Open AccessConflicts of Interest: Owens’ Response
- Open Access
- 1 September 2003
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 111 (12) , 1527-1529
The OECD program to validate the rat uterotrophic bioassay: an overview.
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.
- 1 September 2003
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 111 (12) , 1527-1529
Open AccessThe OECD program to validate the rat uterotrophic bioassay: an overview.
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.
- Open Access
- 1 September 2003
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 111 (12) , 1559-1567
The OECD program to validate the rat uterotrophic bioassay. Phase 2: dietary phytoestrogen analyses.
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.
- 1 September 2003
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 111 (12) , 1559-1567
Open AccessThe OECD program to validate the rat uterotrophic bioassay. Phase 2: dietary phytoestrogen analyses.
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.
- 1 January 2002
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 32 (6) , 445-520
Critical Review and Evaluation of the Uterotrophic Bioassay for the Identification of Possible Estrogen Agonists and Antagonists: In Support of the Validation of the OECD Uterotrophic Protocols for the Laboratory Rodent
A current issue for regulatory agencies is endocrine-related modes of action such as those mediated by the estrogen, androgen, and thyroid nuclear receptors. At the national and international levels, the consensus recommendation for the assessment of such modes of action is a tiered series of in vitro and in vivo protocols. The tiered framework begins with screens for structural alerts and then moves to rapid, mechanistic in vitro screening assays, and then to in vivo screening bioassays. The objective of these screens is to identify substances that may warrant testing for endocrine-mediated adverse effects. The final framework tier as needed is to test these substances in long-term bioassays for adverse endocrine-mediated reproductive and/or developmental effects. The subject of this review, the rodent uterotrophic bioassay, is intended to be a rapid in vivo screening bioassay for possible estrogen agonists and antagonists, based on the response of the estrogen-sensitive uterus. The central metric of the bioassay is a statistically significant increase in the weight of the uterus after 3 consecutive days of test substance administration. The extensive background literature is summarized in this review on the mode of action underlying the bioassay and the uterine response to estrogens. The review includes the bioassay's history of development and how its employment has changed and evolved over time. The review describes two major uterotrophic bioassay versions, the intact, immature female and the mature, ovariectomized female, and the protocol factors likely to influence the relevance, reproducibility, and reliability of the bioassay. The emphasis of the review is the ability of the uterotrophic bioassay to identify the substances of current interest: weak estrogen agonists with binding affinities relative to the natural 17β-estradiol in the log 0 to log -3 range. Using selected model substances having RBAs in this target range, the bioassay's performance in a hierarchical, tiered approach is evaluated, including the predictive capability of the uterotrophic bioassay based on available reproductive and developmental testing data. The review concludes that the uterotrophic bioassay is reliable and can identify substances that may act via an estrogen-mode of action, supporting the validity of the uterotrophic bioassay and its regulatory use as an in vivo mechanistic screening bioassay for estrogen agonists and antagonists.
- 1 January 2002
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 32 (6) , 445-520
Critical Review and Evaluation of the Uterotrophic Bioassay for the Identification of Possible Estrogen Agonists and Antagonists: In Support of the Validation of the OECD Uterotrophic Protocols for the Laboratory Rodent
A current issue for regulatory agencies is endocrine-related modes of action such as those mediated by the estrogen, androgen, and thyroid nuclear receptors. At the national and international levels, the consensus recommendation for the assessment of such modes of action is a tiered series of in vitro and in vivo protocols. The tiered framework begins with screens for structural alerts and then moves to rapid, mechanistic in vitro screening assays, and then to in vivo screening bioassays. The objective of these screens is to identify substances that may warrant testing for endocrine-mediated adverse effects. The final framework tier as needed is to test these substances in long-term bioassays for adverse endocrine-mediated reproductive and/or developmental effects. The subject of this review, the rodent uterotrophic bioassay, is intended to be a rapid in vivo screening bioassay for possible estrogen agonists and antagonists, based on the response of the estrogen-sensitive uterus. The central metric of the bioassay is a statistically significant increase in the weight of the uterus after 3 consecutive days of test substance administration. The extensive background literature is summarized in this review on the mode of action underlying the bioassay and the uterine response to estrogens. The review includes the bioassay's history of development and how its employment has changed and evolved over time. The review describes two major uterotrophic bioassay versions, the intact, immature female and the mature, ovariectomized female, and the protocol factors likely to influence the relevance, reproducibility, and reliability of the bioassay. The emphasis of the review is the ability of the uterotrophic bioassay to identify the substances of current interest: weak estrogen agonists with binding affinities relative to the natural 17β-estradiol in the log 0 to log -3 range. Using selected model substances having RBAs in this target range, the bioassay's performance in a hierarchical, tiered approach is evaluated, including the predictive capability of the uterotrophic bioassay based on available reproductive and developmental testing data. The review concludes that the uterotrophic bioassay is reliable and can identify substances that may act via an estrogen-mode of action, supporting the validity of the uterotrophic bioassay and its regulatory use as an in vivo mechanistic screening bioassay for estrogen agonists and antagonists.
- 1 January 2002
- Vol. 21 (1) , 207-25
Chemical toxicity indicators for human health: case study for classification of chronic noncancer chemical hazards in life-cycle assessment.
The classification scheme for human health indicators in life-cycle assessment (LCA) and other toxicity scores is proposed based on identifiable target organ or system toxicity. This scheme represents a compromise between a subjective single overall score and highly detailed toxic mechanisms of action. A case study was used to evaluate the proposed classification scheme. The data on 117 high production volume organic chemicals were extracted from the U.S. Environmental Protection Agency (U.S. EPA) integrated risk information system (IRIS) database. Based on the critical effect listed in the database, almost all chemicals were easily and clearly classified into the proposed categories. However, there were significant variations in test species, protocol, duration, toxicological parameter measured, etc., among different toxicity studies. Importantly, the toxicological critical effects observed, even for the same target organ or system, differed from chemical to chemical and were not equivalent. Using hepatotoxicity as an example, critical effects included changes in organ weight, a variety of different histopathological changes, and changes in circulating hepatic enzyme levels. Therefore, no universal, common basis was identified for biological equivalency in order to compare or to aggregate chemicals into an overall toxicity score. A recent proposal to develop a characterization system based on disability-adjusted life years (DALYs) was also evaluated. No means were found to extrapolate animal critical effects data to predict any diminution in human lifetimes or the appearance and intensity of human disability. Still, LCA presents an ideal starting point for toxicological analysis by conducting a system-wide analysis that inventories and maps the sources of potentially important human pollutants. The LCA results could then facilitate initial toxicological and risk evaluations for those sources and chemicals and set the stage for a more detailed and informed analysis by professional toxicologists.
- 1 January 2002
- Vol. 21 (1) , 207-25
Chemical toxicity indicators for human health: case study for classification of chronic noncancer chemical hazards in life-cycle assessment.
The classification scheme for human health indicators in life-cycle assessment (LCA) and other toxicity scores is proposed based on identifiable target organ or system toxicity. This scheme represents a compromise between a subjective single overall score and highly detailed toxic mechanisms of action. A case study was used to evaluate the proposed classification scheme. The data on 117 high production volume organic chemicals were extracted from the U.S. Environmental Protection Agency (U.S. EPA) integrated risk information system (IRIS) database. Based on the critical effect listed in the database, almost all chemicals were easily and clearly classified into the proposed categories. However, there were significant variations in test species, protocol, duration, toxicological parameter measured, etc., among different toxicity studies. Importantly, the toxicological critical effects observed, even for the same target organ or system, differed from chemical to chemical and were not equivalent. Using hepatotoxicity as an example, critical effects included changes in organ weight, a variety of different histopathological changes, and changes in circulating hepatic enzyme levels. Therefore, no universal, common basis was identified for biological equivalency in order to compare or to aggregate chemicals into an overall toxicity score. A recent proposal to develop a characterization system based on disability-adjusted life years (DALYs) was also evaluated. No means were found to extrapolate animal critical effects data to predict any diminution in human lifetimes or the appearance and intensity of human disability. Still, LCA presents an ideal starting point for toxicological analysis by conducting a system-wide analysis that inventories and maps the sources of potentially important human pollutants. The LCA results could then facilitate initial toxicological and risk evaluations for those sources and chemicals and set the stage for a more detailed and informed analysis by professional toxicologists.
- 1 January 2002
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 21 (1) , 207-225
CHEMICAL TOXICITY INDICATORS FOR HUMAN HEALTH: CASE STUDY FOR CLASSIFICATION OF CHRONIC NONCANCER CHEMICAL HAZARDS IN LIFE-CYCLE ASSESSMENT
The classification scheme for human health indicators in life-cycle assessment (LCA) and other toxicity scores is proposed based on identifiable target organ or system toxicity. This scheme represent...
- 1 January 2002
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 21 (1) , 207-225
CHEMICAL TOXICITY INDICATORS FOR HUMAN HEALTH: CASE STUDY FOR CLASSIFICATION OF CHRONIC NONCANCER CHEMICAL HAZARDS IN LIFE-CYCLE ASSESSMENT
The classification scheme for human health indicators in life-cycle assessment (LCA) and other toxicity scores is proposed based on identifiable target organ or system toxicity. This scheme represent...
- 1 April 2001
- Published by Springer Nature in Journal of Industrial Ecology
- Vol. 5 (2) , 37-54
Water Resources in Life‐Cycle Impact Assessment: Considerations in Choosing Category Indicators
Summary: Water is one of many resources, wastes, and pollutants considered in life‐cycle assessment (LCA). The widely used indicator for water resources, the total input of water used, is not adequate to assess water resources from a sustainability perspective. More detailed indicators are proposed for water resources in two areas essential to water sustainability: water quantity and water quality. The governing principles for a consideration of water quantity are that (1) the water sources or LCA inputs are renewable and sustainable and (2) the volume of water released or LCA outputs are returned to humans or ecosystems for further use downstream. The governing principle for a consideration of water quality is that the utility of the returned water is not impaired for either humans or ecosystems downstream. Water quantity indicators are defined for water use, consumption, and depletion to reveal the sustainable or nonsustainable nature of the sources. A flexible set of water quality indicators for various factors that may impair water quality are then discussed, including the LCA study choices, technical challenges, and trade‐offs involved with such indicators. Indicator selection from this set involves the underlying concern or endpoint represented by the indicator and the level and accuracy of decision‐making information that the indicator must provide. With significant differences in emissions among systems studied using LCA and different purposes of the LCA studies themselves, a single, default set of water quality indicators applicable to all systems studied with LCA is problematic. The proposed water quantity and quality indicators for LCA studies are also intended to be compatible with environmental management and reporting systems so that data needs are not duplicated and interpretation for one does not contradict or sow confusion for the other.
- 1 April 2001
- Published by Springer Nature in Journal of Industrial Ecology
- Vol. 5 (2) , 37-54
Water Resources in Life‐Cycle Impact Assessment: Considerations in Choosing Category Indicators
Summary: Water is one of many resources, wastes, and pollutants considered in life‐cycle assessment (LCA). The widely used indicator for water resources, the total input of water used, is not adequate to assess water resources from a sustainability perspective. More detailed indicators are proposed for water resources in two areas essential to water sustainability: water quantity and water quality. The governing principles for a consideration of water quantity are that (1) the water sources or LCA inputs are renewable and sustainable and (2) the volume of water released or LCA outputs are returned to humans or ecosystems for further use downstream. The governing principle for a consideration of water quality is that the utility of the returned water is not impaired for either humans or ecosystems downstream. Water quantity indicators are defined for water use, consumption, and depletion to reveal the sustainable or nonsustainable nature of the sources. A flexible set of water quality indicators for various factors that may impair water quality are then discussed, including the LCA study choices, technical challenges, and trade‐offs involved with such indicators. Indicator selection from this set involves the underlying concern or endpoint represented by the indicator and the level and accuracy of decision‐making information that the indicator must provide. With significant differences in emissions among systems studied using LCA and different purposes of the LCA studies themselves, a single, default set of water quality indicators applicable to all systems studied with LCA is problematic. The proposed water quantity and quality indicators for LCA studies are also intended to be compatible with environmental management and reporting systems so that data needs are not duplicated and interpretation for one does not contradict or sow confusion for the other.